

Application No. 09/724,575
Amendment dated July 31, 2006
Reply to Office Action of March 31, 2006

RECEIVED
CENTRAL FAX CENTER
JUL 31 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-10. (Canceled)

11. (Currently Amended) A method of therapeutically treating a patient suffering from Alzheimer's disease, comprising peripherally administering to the patient a dosage of a chimeric, humanized or human antibody or antibody fragment thereof that specifically binds [[a]] the NAC fragment of α -synuclein and a dosage of a chimeric, humanized or human antibody or antibody fragment thereof that specifically binds to an epitope within residues 1-28 of A β , and thereby therapeutically treating the disease.

12-57. (Canceled)

58. (Currently Amended) A method of prophylactically treating a patient susceptible to Alzheimer's disease, comprising peripherally administering to the patient a dosage of a chimeric, humanized or human antibody or antibody fragment thereof that specifically binds[[a]] the NAC fragment of α -synuclein and a dosage of a chimeric, humanized or human antibody or antibody fragment thereof that specifically binds to an epitope within residues 1-28 of A β , and thereby effecting prophylaxis of the disease.

59-73. (Canceled)

74. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered with a carrier.

75. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically, or intravenously.

Application No. 09/724,575
Amendment dated July 31, 2006
Reply to Office Action of March 31, 2006

76. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered in multiple dosages over a period of at least six months.

77. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered as a sustained release composition.

78. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered with a carrier.

79. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically, or intravenously.

80. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered in multiple dosages over a period of at least six months.

81. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered as a sustained release composition.